NASDAQ:NUVA - NuVasive Stock Price, Forecast & News

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Wednesday, October, 30th. The medical device company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.53 by $0.06. The medical device company earned $290.80 million during the quarter, compared to analysts' expectations of $283.75 million. NuVasive had a net margin of 4.15% and a return on equity of 14.93%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.56 EPS. View NuVasive's Earnings History.

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for NuVasive.

NuVasive issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $310-310 million, compared to the consensus revenue estimate of $304.32 million.

17 equities research analysts have issued 12 month price targets for NuVasive's stock. Their forecasts range from $55.00 to $93.00. On average, they anticipate NuVasive's stock price to reach $76.63 in the next twelve months. This suggests that the stock has a possible downside of 1.0%. View Analyst Price Targets for NuVasive.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.

News articles about NUVA stock have been trending somewhat negative on Tuesday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NuVasive earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for NuVasive.

NuVasive saw a increase in short interest in December. As of December 13th, there was short interest totalling 4,100,000 shares, an increase of 7.0% from the November 28th total of 3,830,000 shares. Based on an average daily trading volume, of 509,600 shares, the short-interest ratio is presently 8.0 days. Currently, 7.9% of the shares of the company are sold short. View NuVasive's Current Options Chain.

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Medivation (MDVN), Starbucks (SBUX), Alibaba Group (BABA), Intel (INTC), Global Sources Ltd. (Bermuda) (GSOL), Celgene (CELG) and Skyworks Solutions (SWKS).

NuVasive's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Anchor Capital Advisors LLC (2.41%), Copper Rock Capital Partners LLC (0.56%), California Public Employees Retirement System (0.28%), Janney Montgomery Scott LLC (0.10%), New York State Teachers Retirement System (0.07%) and Arizona State Retirement System (0.06%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Institutional Ownership Trends for NuVasive.

NUVA stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Janney Montgomery Scott LLC, Nisa Investment Advisors LLC, Diversified Trust Co, Eqis Capital Management Inc., Virginia Retirement Systems ET AL, Dupont Capital Management Corp and Weatherly Asset Management L. P.. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Insider Buying and Selling for NuVasive.

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, Copper Rock Capital Partners LLC, California Public Employees Retirement System, Strs Ohio, Acorn Financial Advisory Services Inc. ADV, New York State Teachers Retirement System, Carroll Financial Associates Inc. and Valeo Financial Advisors LLC. View Insider Buying and Selling for NuVasive.

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NUVA stock can currently be purchased for approximately $77.41.

NuVasive has a market capitalization of $4.03 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.

The official website for NuVasive is http://www.nuvasive.com/.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]